Gilead Sciences Inc.’s recent decision to acquire Immunomedics Inc. looks even smarter now in light of the full data in a phase III study of Trodelvy (sacituzumab govitecan-hziy) released at the European Society for Medical Oncology (ESMO) over the weekend.
Gastric cancers were the focus of the final plenary session of the European Society for Medical Oncology’s Virtual Congress 2020. Results from the Checkmate-649, ATTRACTION-4, and Keynote-590 studies showed that advanced gastroesophageal tumors can benefit from first-line treatment with PD-1 checkpoint blockers in addition to chemotherapy, staving off progression and death by a few months.
One of the highlights of the first presidential program at this year’s European Society for Medical Oncology 2020 Virtual Congress were results from the Checkmate 9ER study by Toni Choueiri, who is the director of the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute. Checkmate 9ER tested the use of a combination of checkpoint blocker Opdivo (nivolumab, Bristol Myers Squibb Co.) and receptor tyrosine kinase inhibitor Cabometyx (cabozantinib, Exelixis Inc.) as first-line treatment for advanced renal cell carcinoma.
CDK 4/6 inhibitor Verzenio (abemaciclib, Eli Lilly and Co.) reduced the risk of recurrence in women with high-risk hormone receptor driven and HER2-negative breast cancer when added to endocrine therapy in the monarchE phase III trial.
New and updated preclinical and clinical data presented by biopharma firms at the European Society for Medical Oncology Virtual Congress 2020, including: Amgen, Astrazeneca, Bayer, Blueprint, BMS, Chi-Med, Eisai, Exelixis, Genentech, Genmab, Immunomedics, Innovent, Ipsen, Janssen, Lilly, Macrogenics, Merck, Novartis, Oncternal, Ose, Pieris, Regeneron, Roche, Sanofi, Seattle Genetics, Veru.
New and updated preclinical and clinical data to be presented by biopharma firms at the European Society for Medical Oncology Virtual Congress 2020, including: Agenus, Alkermes, Astrazeneca, Autolus, Ayala, Beigene, Daiichi, Deciphera, Eisai, Essa, Faron, Helsinn, Immunomedics, Immutep, Incyte, IO, Ipsen, Italfarmaco, Menarini, Mirati, Regeneron, Sanofi, Sensei, Spectrum, Sumitomo, Takeda.
New and updated preclinical and clinical data to be presented by biopharma firms at the
European Society for Medical Oncology Virtual Congress 2020, including: ADC, Amunix, Bayer, Blueprint, BMS, Cardiff Oncology, Clovis, Corvus, Cullinan Pearl, Deciphera, Genentech, Genocea, Halozyme, Immunicum, Immunogen, Mersana, Noxxon, Oryzon, Roche, VBI.
There's a yin and yang to neoantigens, Alberto Bardelli told the audience at the 2019 annual conference of the European Society of Medical Oncology (ESMO) in Barcelona, Spain, last month. They contribute to tumorigenesis, resistance and tumor heterogeneity. But they are also often specific to tumor cells but not normal cells and "some," he said, "are actionable targets."
RSS
